专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090131349A1 Methods and Compositions for Modulating Body Weight and for Treating Weight Disorders and Related Diseases 审中-公开
标题翻译：调节体重和治疗体重障碍及相关疾病的方法和组合
公开(公告)号：US20090131349A1
公开(公告)日：2009-05-21
申请号：US11885633
申请日：2006-02-23
申请人： Ari Elson , Richard Klinghoffer
发明人： Ari Elson , Richard Klinghoffer
IPC分类号： A61K31/7088
CPC分类号： C12N9/16 , C12N15/1137 , C12N15/1138 , C12N2310/14 , C12N2310/53 , C12Y301/03048
摘要： Methods of modulating body weight and/or fat content of a subject, methods of treating or preventing weight disorders and methods of treating or preventing weight disorder related diseases are disclosed. The methods include modifying an activity or expression of a protein tyrosine phosphatase epsilon (PTPe) so as to modulate the body weight and/or fat content of the subject. Pharmaceutical compositions and articles of manufacture useful in practice of the methods are further disclosed.
摘要翻译：公开了调节受试者的体重和/或脂肪含量的方法，治疗或预防体重紊乱的方法以及治疗或预防体重紊乱相关疾病的方法。所述方法包括修饰蛋白酪氨酸磷酸酶ε（PTPe）的活性或表达，以便调节受试者的体重和/或脂肪含量。进一步公开了在实践该方法中有用的药物组合物和制品。

2. 发明授权

US08852590B2 Compositions and methods for treating cancer 有权
标题翻译：用于治疗癌症的组合物和方法
公开(公告)号：US08852590B2
公开(公告)日：2014-10-07
申请号：US13264060
申请日：2010-04-06
申请人： Sriram Sathyanarayanan , Christopher Winter , Richard Klinghoffer
发明人： Sriram Sathyanarayanan , Christopher Winter , Richard Klinghoffer
IPC分类号： A61K39/395 , A61P35/00 , A61K31/4353
CPC分类号： A61K31/4353 , A61K39/395 , A61K39/39541 , A61K2300/00
摘要： A method of treating a cancer with an mTOR inhibitor and an anti-IGF-1 R antibody is disclosed.
摘要翻译：公开了一种用mTOR抑制剂和抗IGF-1R抗体治疗癌症的方法。

3. 发明申请

US20120027757A1 COMPOSITIONS AND METHODS FOR TREATING CANCER 有权
标题翻译：用于治疗癌症的组合物和方法
公开(公告)号：US20120027757A1
公开(公告)日：2012-02-02
申请号：US13264060
申请日：2010-04-06
申请人： Sriram Sathyanarayanan , Christopher Winter , Richard Klinghoffer
发明人： Sriram Sathyanarayanan , Christopher Winter , Richard Klinghoffer
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K31/4353 , A61K39/395 , A61K39/39541 , A61K2300/00
摘要： A method of treating a cancer with an mTOR inhibitor and an anti-IGF-1 R antibody is disclosed.
摘要翻译：公开了一种用mTOR抑制剂和抗IGF-1R抗体治疗癌症的方法。

4. 发明申请

US20140114279A1 MODULATION NEURAL PATHWAYS 审中-公开
标题翻译：调节神经途径
公开(公告)号：US20140114279A1
公开(公告)日：2014-04-24
申请号：US13637274
申请日：2011-11-23
申请人： Richard Klinghoffer
发明人： Richard Klinghoffer
IPC分类号： A61M5/32 , A61M5/142
CPC分类号： A61K49/0004 , A61K49/0008 , A61M5/1408 , A61M5/142 , A61M5/14212 , A61M5/3298 , A61M37/00
摘要： An administration device comprising an array of needles, one or more fluid agents, and at least one hydrogel is described. The device can simultaneously deliver a plurality of fluid agents along respective axes into a tissue. The use of hydrogel leads to constrained delivery of the fluid agents. The constrained delivery of an agent is also achieved by depositing a drug implant into a tissue. The effect of an agent on the tissue can be evaluated thereafter. In addition, the invention is directed to treating muscle diseases by delivering a therapeutic agent in vivo, and the use of reporter tissues for candidate drug evaluation, detecting and characterizing resistance.
摘要翻译：描述了包括针阵列，一种或多种流体试剂和至少一种水凝胶的给药装置。该装置可以同时沿着各个轴将多个流体试剂输送到组织中。水凝胶的使用导致流体试剂的约束递送。药剂的约束递送也通过将药物植入物沉积到组织中来实现。此后可以评估药剂对组织的作用。此外，本发明涉及通过在体内递送治疗剂来治疗肌肉疾病，以及使用报道组织进行候选药物评价，检测和表征耐药性。

5. 发明授权

US07399586B2 Modulation of biological signal transduction by RNA interference 失效
标题翻译：通过RNA干扰调节生物信号转导
公开(公告)号：US07399586B2
公开(公告)日：2008-07-15
申请号：US10444795
申请日：2003-05-23
申请人： Richard Klinghoffer , Stephen Patrick Lewis
发明人： Richard Klinghoffer , Stephen Patrick Lewis
IPC分类号： C12Q1/68 , C12P19/34 , C12N15/03 , C12N15/00 , C07N21/04
CPC分类号： C12N15/1137 , A61K38/00 , C12N2310/111 , C12N2310/14 , C12N2310/3517 , C12N2310/53 , C12Y301/03048
摘要： Compositions and methods relating to small interfering RNA (siRNA) polynucleotides are provided as pertains to modulation of biological signal transduction. Shown are siRNA polynucleotides that interfere with expression of members of the protein tyrosine phosphatase (PTP) class of enzymes that mediate signal transduction, and with certain MAP kinase kinases (MKK). In certain preferred embodiments siRNA modulate signal transduction pathways comprising SHP2, cdc14a/b, cdc25A/B/C, KAP, PTP-ε, PRL-3, CD45, dual specificity phosphatase-3 (DSP-3), MKK-4, and/or MKK-7. Modulation of PTP-mediated biological signal transduction has uses in diseases associated with defects in cell proliferation, cell differentiation and/or cell survival, such as metabolic disorders (including diabetes and obesity), cancer, autoimmune disease, infectious and inflammatory disorders and other conditions. The invention also provides siRNA polynucleotides that interfere with expression of chemotherapeutic target polypeptides, such as DHFR, thymidylate synthetase, and topoisomerase I.
摘要翻译：提供了与小干扰RNA（siRNA）多核苷酸相关的组合物和方法，涉及生物信号转导的调节。显示干扰介导信号转导的酶的蛋白酪氨酸磷酸酶（PTP）类成员和某些MAP激酶激酶（MKK）的成员的表达的siRNA多核苷酸。在某些优选实施方案中，siRNA调节包含SHP2，cdc14a / b，cdc25A / B / C，KAP，PTP-ε，PRL-3，CD45，双特异性磷酸酶-3（DSP-3），MKK-4和 /或MKK-7。 PTP介导的生物信号转导的调节在与细胞增殖，细胞分化和/或细胞存活缺陷相关的疾病中使用，例如代谢紊乱（包括糖尿病和肥胖症），癌症，自身免疫性疾病，感染性和炎症性疾病和其他病症。本发明还提供干扰化学治疗靶多肽如DHFR，胸苷酸合成酶和拓扑异构酶I的表达的siRNA多核苷酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式